Las Vegas, NV -- (SBWIRE) -- 09/25/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Cirrus Logic, Inc. (NASDAQ:CRUS), Coeur Mining Inc (NYSE:CDE), VIVUS, Inc. (NASDAQ:VVUS)
Celldex Therapeutics, Inc. (NASDAQ:CLDX) managed to keep its gain at 4.87% on above-normal volume of 4.78M shares. The stock settled at $34.27 after floating in a range of $31.43 to $34.28. Its latest price has reached market capitalization of $2.78 Billion. Its 52-week range has been $5.02 to $34.28. Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.
For How Long CLDX will fight for Profitability? Read This Trend Analysis report
Cirrus Logic, Inc. (NASDAQ:CRUS) traded up on a volume of 3.28 million, higher than its standard daily volume. Shares have gained 1.72% to $23.60. Over the last twelve months, the stock has lost-43.76% and faced a worst price of $16.46. Cirrus Logic, Inc., a fabless semiconductor company, develops analog and mixed-signal integrated circuits (ICs) for a range of consumer and industrial markets.
For How Long CRUS’s Gloss will Attract Investors? Find out via this report
Coeur Mining Inc (NYSE:CDE) settled -2.97% lower at $12.43 on above-normal volume of 3.28M shares during the last trading day. The stock has its 12-month high at $31.97 and 52-week low price was $11.29. It traded in a range of $12.35 to $12.87 during the last trading day. Coeur Mining, Inc., through its subsidiaries, engages in the ownership, operation, exploration, and development of silver and gold mining properties primarily in South America, Mexico, the United States, and Australia.
Will CDE Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, VIVUS, Inc. (NASDAQ:VVUS) was down on high volume, trading at a volume of 3.15M versus its average daily volume of 2.23 million shares. At $9.55, the stock has attained market capitalization of 963.15 million. VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health.
Why Should Investors Buy VVUS After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)